Wang Wei-Lu, Lian Haoran, Liang Yingyu, Ye Yongqin, Tam Paul Kwong Hang, Chen Yan
School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macao SAR, China.
Faculty of Medicine, Macau University of Science and Technology, Macao SAR, China.
Cells. 2024 Dec 3;13(23):1997. doi: 10.3390/cells13231997.
The aim of this review is to explore the potential of new regenerative medicine approaches in the treatment of cholestatic liver fibrosis. Cholestatic liver diseases, such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia (BA), due to the accumulation of bile, often progress to liver fibrosis, cirrhosis, and liver failure. When the disease becomes severe enough to require liver transplantation. Deeply understanding the disease's progression and fibrosis formation is crucial for better diagnosis and treatment. Current liver fibrosis treatments mainly target the root causes and no direct treatment method in fibrosis itself. Recent advances in regenerative medicine offer a potential approach that may help find the ways to target fibrosis directly, offering hope for improved outcomes. We also summarize, analyze, and discuss the current state and benefits of regenerative medicine therapies such as mesenchymal stem cell (MSC) therapy, induced pluripotent stem cells (iPSCs), and organoid technology, which may help the treatment of cholestatic liver diseases. Focusing on the latest research may reveal new targets and enhance therapeutic efficacy, potentially leading to more effective management and even curative strategies for cholestatic liver diseases.
本综述的目的是探讨新型再生医学方法在治疗胆汁淤积性肝纤维化方面的潜力。胆汁淤积性肝病，如原发性胆汁性胆管炎（PBC）、原发性硬化性胆管炎（PSC）和胆道闭锁（BA），由于胆汁积聚，常进展为肝纤维化、肝硬化和肝衰竭。当疾病严重到需要进行肝移植时。深入了解疾病的进展和纤维化形成对于更好的诊断和治疗至关重要。目前的肝纤维化治疗主要针对病因，而没有针对纤维化本身的直接治疗方法。再生医学的最新进展提供了一种潜在的方法，可能有助于找到直接针对纤维化的方法，为改善治疗结果带来希望。我们还总结、分析和讨论了再生医学疗法，如间充质干细胞（MSC）疗法、诱导多能干细胞（iPSC）和类器官技术的现状和益处，这些疗法可能有助于治疗胆汁淤积性肝病。关注最新研究可能会揭示新的靶点并提高治疗效果，有可能为胆汁淤积性肝病带来更有效的管理甚至治愈策略。
